Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-02
DOI
10.1038/s41467-020-19801-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
- (2020) Andrew N Phillips et al. Lancet HIV
- ART adherence and viral suppression are high among most non-pregnant individuals with early-stage, asymptomatic HIV infection: an observational study from Uganda and South Africa
- (2019) Jessica E Haberer et al. Journal of the International AIDS Society
- Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
- (2019) Michael Aboud et al. LANCET INFECTIOUS DISEASES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- The Impact of HIV-1 Drug Escape on the Global Treatment Landscape
- (2019) D.A. Collier et al. Cell Host & Microbe
- Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
- (2019) Rebecca Zash et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- Management of Virologic Failure and HIV Drug Resistance
- (2019) Suzanne M. McCluskey et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact
- (2019) Herbert A Mbunkah et al. JOURNAL OF INFECTIOUS DISEASES
- Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial
- (2019) Michael H Chung et al. Lancet HIV
- OLA-Simple: A software-guided HIV-1 drug resistance test for low-resource laboratories
- (2019) Nuttada Panpradist et al. EBioMedicine
- Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa
- (2018) Seth C Inzaule et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis
- (2018) Ravindra K Gupta et al. LANCET INFECTIOUS DISEASES
- Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial
- (2018) Collins C Iwuji et al. Lancet HIV
- Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance
- (2018) Seth C. Inzaule et al. Scientific Reports
- Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial
- (2018) Anne Derache et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial
- (2018) Laurent Hocqueloux et al. CLINICAL INFECTIOUS DISEASES
- Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART
- (2018) Anne Derache et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
- (2018) Andrew N Phillips et al. Lancet HIV
- Brief Report
- (2017) Jamison Norwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
- (2017) Ingeborg Wijting et al. Lancet HIV
- Undisclosed HIV infection and antiretroviral therapy use in the Kenya AIDS indicator survey 2012
- (2016) Andrea A. Kim et al. AIDS
- Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa
- (2016) Nicholas Musinguzi et al. AIDS
- Brief Report
- (2016) Harriet Okatch et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
- (2016) John Gregson et al. LANCET INFECTIOUS DISEASES
- Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda
- (2016) Jean d'Amour Ndahimana et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey
- (2016) Santiago Ávila-Ríos et al. Lancet HIV
- Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial
- (2015) Rami Kantor et al. CLINICAL INFECTIOUS DISEASES
- Altered Viral Fitness and Drug Susceptibility in HIV-1 Carrying Mutations That Confer Resistance to Nonnucleoside Reverse Transcriptase and Integrase Strand Transfer Inhibitors
- (2014) Z. Hu et al. JOURNAL OF VIROLOGY
- Long-acting HIV drugs advanced to overcome adherence challenge
- (2014) Elie Dolgin NATURE MEDICINE
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies
- (2012) R. L. Hamers et al. CLINICAL INFECTIOUS DISEASES
- Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa
- (2012) Matthew P. Fox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
- (2012) Jonathan Z. Li, Roger Paredes, Heather J. Ribaudo, Michael J. Kozal, Evguenia S. Svarovskaia, Jeffrey A. Johnson, Anna Maria Geretti, Karin J. Metzner et al. JOURNAL OF INFECTIOUS DISEASES
- Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure
- (2011) Jonathan Z. Li et al. AIDS
- Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study
- (2011) Raph L Hamers et al. LANCET INFECTIOUS DISEASES
- Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices
- (2010) Lizheng Shi et al. PHARMACOECONOMICS
- Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa
- (2008) Vincent C. Marconi et al. CLINICAL INFECTIOUS DISEASES
- Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy
- (2008) Jeffrey A Johnson et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now